Tajikistan Medical Device Risk Classification and Reclassification: Rules and Responsibilities

1. Key takeaways

The safety risk classification and reclassification of medical devices in Tajikistan is determined by the authorized state body in the field of health care together with the State Supervisory Authority for Pharmaceutical Activities. The wording of Article 13(5) of Law No. 1893 is that the safety classification of medical devices according to the degree of risk in their use, and their safety reclassification, are determined by the authorized state body in the field of health care jointly with the supervisory authority. GRZAN therefore takes a clear position: the circulating claim that Tajik medical device classification fully adopts the Eurasian Economic Union technical regulations is not adopted here. Tajikistan is not a member of the Union, its classification rules are set jointly by two national bodies, and the law expressly provides a reclassification mechanism that can change a product’s regulatory treatment during its market life.

2. Legal basis

3. Expert insights

Insight 1: Article 13(5) assigns ownership but does not contain the classification rules themselves. The provision answers the question of who determines classification, without setting out the specific criteria, the number of classes or the decision method. These are issued by the two bodies in normative documents. GRZAN judges that the Tajik classification rules for devices are lower-tier, adjustable documents, which differs fundamentally from the catalog-based system of China or the rule-based MDR classification of the European Union. When making a classification determination, companies must obtain the currently valid classification document and cannot rely on historical material, because a change of version can move a product between classes without any change in the product itself.

Insight 2: the reclassification mechanism means a classification outcome is never final. Article 13(5) provides for both classification and reclassification. The provision does not state the triggers for reclassification, but on a systemic reading, risk signals found in post-market surveillance under Article 20, regulatory action taken abroad under Article 20(5) and Article 21(8), and the discovery of design defects under Article 21(1)(12) can all prompt reclassification. GRZAN notes that the direct consequence of reclassification is a change in registration requirements and in the intensity of conformity assessment, so companies should track the classification status of their products continuously after market entry, not only at the filing stage.

Insight 3: Article 13 internally forms a complete chain of classification, assessment and exemption. Paragraph 3 hands the batch-by-batch assessment procedure to the Ministry of Health, paragraph 4 grants the GMP exemption, and paragraph 5 assigns classification ownership. What the three provisions share is leadership by the Ministry of Health. The structural meaning is that the intensity of market access control for devices in Tajikistan is implemented mainly through technical documents of the Ministry of Health rather than through rigid statutory text. For companies, the lesson is that the primary counterpart for technical communication is the technical department of the Ministry of Health.

Insight 4: classification and the registration exemption list of Article 17(4) are two different thresholds. Article 17(4) decides whether registration is required at all, while the classification under Article 13(5) decides at what intensity the product is assessed. A product may fall outside the nine registration-exemption situations and must therefore be registered, yet because of a low risk class it may follow a lighter assessment path. When companies evaluate the difficulty of market access, they should calculate these two thresholds separately instead of merging them into a single judgment, because the two gates can move independently of each other.

4. Practical recommendations

1. Obtain the currently valid classification document at project initiation. GRZAN recommends that at the start of every project the current safety classification document for medical devices be requested from the Ministry of Health and used as the sole basis for the classification determination, with the document version recorded in the project file.
2. Build reclassification risk into post-market surveillance. Preset trigger points in the quality system: reclassification of the product in another country, new risk signals after market entry, or any change in design or intended use should each launch a review of the classification status under Article 13(5).
3. Pursue classification arguments and technical communication in parallel. Because Article 13(5) assigns classification to the Ministry of Health, any technical defense of a classification decision should be addressed to the technical department of the Ministry of Health rather than to the supervisory authority alone.
4. Keep the registration threshold and the assessment intensity separate. In the project evaluation form, record whether registration is required under Article 17(4) and under which risk class the product is assessed under Article 13(5) as two independent fields, each with its own documented basis.

5. Verification checklist

• □ Confirmed the ownership of classification and reclassification under Article 13(5), by the Ministry of Health jointly with the supervisory authority
• □ Obtained the currently valid safety classification document for medical devices and recorded its version
• □ Preset the reclassification trigger points in the quality system
• □ Confirmed that the counterpart for technical classification arguments is the technical department of the Ministry of Health
• □ Separated the fields for whether registration is required and at which class the product is assessed in the project evaluation form
• □ Confirmed whether the GMP exemption of Article 13(4) applies to the product
• □ Tracked post-market changes in classification status and updated the registration strategy accordingly

Regulatory information verified as of October 29, 2026.

In the Central Asian market, the core capabilities of GRZAN concentrate on three areas. First, distinguishing the different legal positions of each market within the Eurasian Economic Union: Kazakhstan and Kyrgyzstan are full member states where a dual-track choice exists between the national route and the Union route; Uzbekistan is an observer state with only a national route; Tajikistan and Turkmenistan sit outside the Union framework and must follow purely national procedures. Second, local authorized representative services: GRZAN acts as the statutory representative of manufacturers in these countries and undertakes registration submissions, regulatory communication and post-market reporting obligations. Third, quality system and testing support: GRZAN helps establish a quality management system conforming to ISO 13485 and connects clients with locally accredited laboratory resources.

Business inquiries: info@grzanglobal.com